Sleep disruption in critically ill patients - Pharmacological ocnsiderations

Anaesthesia

Volumn 59, Issue 4, 2004, Pages 374-384

  Bourne, Richard S ^a   Mills, G H ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Drug therapy: Complication; Intensive care; Sleep disorders

Indexed keywords

ADRENALIN; AMINOPHYLLINE; AMIODARONE; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLONIDINE; CORTICOSTEROID; DEXMEDETOMIDINE; DOPAMINE; HYPNOTIC AGENT; INOTROPIC AGENT; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OPIATE; PHENOBARBITAL; PHENYTOIN; PROTECTIVE AGENT; QUINOLONE DERIVATIVE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACUTE DISEASE; ARTIFICIAL VENTILATION; BLOOD BRAIN BARRIER; CRITICAL ILLNESS; DRUG ABUSE; DRUG INDICATION; DRUG RESEARCH; DRUG USE; ENVIRONMENTAL FACTOR; EXPERIENCE; HALLUCINATION; HEART PROTECTION; HUMAN; INSOMNIA; MORBIDITY; NIGHTMARE; NONHUMAN; PATIENT CARE; PERCEPTION; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; REM SLEEP; REVIEW; SLEEP DISORDER; SLOW WAVE SLEEP; STOMACH PROTECTION; STRESS; WITHDRAWAL SYNDROME;

CRITICAL ILLNESS; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; SLEEP DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 1842844354     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2004.03664.x     Document Type: Review

References (114)

1. Cooper AB, Thornley KS, Young GB et al. Sleep in critically ill patients requiring mechanical ventilation. Chest 2000; 117: 809-18.
2. Eveloff SE. The disruptive ICU. An issue to lose sleep over? Chest 1995; 107: 1483-4.
3. Gabor JY, Cooper AB, Hanly PJ. Sleep disruption in the intensive care unit. Current Opinion in Critical Care 2001; 7: 21-7.
4. Freedman NS, Kotzer N, Schwab RJ. Patient perception of sleep quality and etiology of sleep disruption in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 1999; 159: 1155-62.
5. Nelson JE, Meier DE, Oei EJ et al. Self-reported symptom experience of critically ill cancer patients receiving intensive care. Critical Care Medicine 2001; 29: 277-82.
6. Novaes MA, Aronovich A, Ferraz MB, Knobel E. Stressors in ICU. patients' evaluation. Intensive Care Medicine 1997; 23: 1282-5.
7. Fleetham J, West P, Mezon B et al. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. American Review of Respiratory Disease 1982; 126: 429-33.
8. Quaranta AJ, D'Alonzo GE, Krachman SL. Cheyne-Stokes respiration during sleep in congestive heart failure. Chest 1997; 111: 467-73.
9. Dowell AR, Buckley CE 3rd, Cohen R, Whalen RE, Sieker HO. Cheyne-Stokes respiration. A review of clinical manifestations and critique of physiological mechanisms. Archives of Internal Medicine 1971; 127: 712-26.
10. Janson C, Gislason T, Boman G, Hetta J, Roos BE. Sleep disturbances in patients with asthma. Respiratory Medicine 1990; 84: 37-42.
11. Krachman SL, D'Alonzo GE, Criner GJ. Sleep in the intensive care unit. Chest 1995; 107: 1713-20.
12. Freedman NS, Gazendam J, Levan L, Pacj AI, Schwab RJ. Abnormal sleep/wake cycles and the effect of environmental noise on sleep disruption in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 2001; 163: 451-7.
13. Gabor JY, Cooper AB, Crombach SA et al. Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects. American Journal of Respiratory and Critical Care Medicine 2003; 167: 708-15.
14. Drucker-Colin R, Merchant-Nancy H. Evolution of concepts of mechanisms of sleep. In: Kales, A, ed. Handbook of Experimental Pharmacology: Pharmacology of Sleep. Berlin: Springer-Verlag 1995, 116: 1-28.
15. Porkka Heiskanen T, Alanko L, Kalinchuk A, Stenberg D. Adenosine and sleep. Sleep Medicine Reviews 2002; 6: 321-32.
16. Sack RL, Hughes RJ, Edgar DM, Lewy AJ. SLeep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 1997; 20: 908-15.
17. Dietrich B. Polysomnography in drug development. Journal of Clinical Pharmacology 1997; 37: 70S-8S.
18. Jones C, Griffiths RD, Humphris G, Skirrow PM. Memory, delusions, and the development of acute posttraumatic stress disorder-related symptoms after intensive care. Critical Care Medicine 2001; 29: 573-80.
19. Rundshagen I, Schnabel K, Wegner C, am Esch S. Incidence of recall, nightmares, and hallucinations during analgosedation in intensive care. Intensive Care Medicine 2002; 28: 38-43.
20. Eddleston JM, White P, Guthrie E. Survival, morbidity, and quality of life after discharge from intensive care. Critical Care Medicine 2000; 28: 2293-9.
21. Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Human Neurobiology 1985; 4: 189-94.
22. Achermann P, Borbély AA. Dynamics of EEG slow wave activity during physiological sleep and after administration of benzodiazepine hypnotics. Human Neurobiology 1987; 6: 203-10.
23. Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO. Postoperative sleep disturbance: influences of opioids and pain in humans. Sleep 2001; 24: 39-44.
24. Kinzie JD, Sack RL, Riley CM. The polysomnographic effects of clonidine on sleep disorders in posttraumatic stress disorder: a pilot study with Cambodian patients. Journal of Nervous and Mental Disease 1994; 182: 585-7.
25. Gentili A, Godschalk MF, Gheorghiu D et al. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. European Journal of Clinical Pharmacology 1996; 50: 463-5.
26. Seidel WF, Maze M, Dement WC, Edgar DM. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat. Journal of Pharmacology and Experimental Therapeutics 1995; 275: 263-73.
27. Nelson BJ, Weinert CR, Bury CL, Marinelli WA, Gross CR. Intensive care unit drug use and subsequent quality of life in acute lung injury patients. Critical Care Medicine 2000; 28: 3626-30.
28. Murphy PJ, Badia P, Myers BL, Boecker MR, Wright KP Jr. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiology and Behavior 1994; 55: 1063-6.
29. Murphy PJ, Myers BL, Badia P. Nonsteroid anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiology and Behaviour 1996; 59: 133-9.
30. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. American Journal of Physiology 1971; 221: 1629-39.
31. Myburgh JA, Upton RN, Grant C, Martinez A. The cerebrovascular effects of adrenaline, noradrenaline and dopamine infusions under propofol and isoflurane anaesthesia in sheep. Anaesthesia and Intensive Care 2002; 30: 725-33.
32. Fortin D, McCormick CI, Remsen LG, Nixon R, Neuwelt EA. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 2000; 47: 199-207.
33. Andrzejowski J, Sleigh JW, Johnson IA, Sikiotis L. The effect of intravenous epinephrine on the bispectral index and sedation. Anaesthesia 2000; 55: 761-3.
34. Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. European Journal of Clinical Pharmacology 1985; 28: 69-72.
35. Kales A, Bixler EO, Vela-Bueno A et al. Effects of nadolol on blood pressure, sleep efficiency, and sleep stages. Clinical Pharmacology and Therapeutics 1988; 43: 655-62.
36. Brismar K, Hylander B, Eliasson K, Rossner S, Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Medica Scandinavica 1988; 223: 525-30.
37. Reiffel JA. Intravenous amiodarone in the management of atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 1999; 4: 199-204.
38. Brezis M, Michaeli J, Hamburger R. Nightmares from digoxin. Annals of Internal Medicine 1980; 93: 639-40.
39. Guillot F, Misslin P, Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. Journal of Cardiovascular Pharmacology 1993; 21: 339-46.
40. Keech AC, Armitage JM, Wallendszus KR et al. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group. British Journal of Clinical Pharmacology 1996; 42: 483-90.
41. Earnest D, Robinson M, Rodriguez-Stanley S et al. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Alimentary Pharmacology and Therapeutics 2000; 14: 911-8.
42. Losec Summary of Product Characteristics. Astra Zeneca UK Ltd. July 2002. Available from: http://emc.vhn.net (February 2003).
43. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. American Journal of Gastroenterology 1999; 94: 1230-4.
44. Saxe TG. Metoclopramide side effects. Annals of Internal Medicine 1983; 98: 673-4.
45. Turner R, Elson E. Sleep disorders. Steroids cause sleep disturbance. British Medical Journal 1993; 306: 1477-8.
46. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. Journal of Rheumatology 1998; 25: 1995-2002.
47. Espinoza H, Antic R, Thornton AT, McEvoy RD. The effects of aminophylline on sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. American Review of Respiratory Disease 1987; 136: 80-4.
48. Janson C, Gislason T, Almqvist M, Boman G. Theophylline disturbs sleep mainly in caffeine-sensitive persons. Pulmonary Pharmacology 1989; 2: 125-9.
49. Janson C, Gislason T, Laxmyr L, Boman G, Persson C. Sleep disturbances in asthma: theophylline versus enprofylline. Upsala Journal of Medical Sciences 1991; 96: 119-27.
50. Hendeles L, Weinberger M. Avoidance of adverse effects during chronic therapy with theophylline. Drug Intelligence and Clinical Pharmacy 1980; 14: 522-30.
51. Benca RM, Quintas J. Sleep and host defenses: a review. Sleep 1997; 20: 1027-37.
52. Spath Schwalbe E, Hansen K, Schmidt F et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. Journal of Clinical Endocrinology and Metabolism 1998; 83: 1573-9.
53. Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U. Possible interaction of fluoroquinolones; with the benzodiazepine-GABA-receptor complex. British Journal of Clinical Pharmacology 1990; 30: 63-70.
54. Zyvox Summary of Product Characteristics. Pharmacia Ltd, August, 2002. Available from: http://emc.vhn.net. (February 2003).
55. Gillin JC, Jernajczyk W, Valladares-Neto DC et al. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacologia 1994; 116: 433-6.
56. Kupfer DJ, Ehlers CL, Pollock BG, Nathan RS, Perel JM. Clomipramine and EEG sleep in depression. Psychiatry Research 1989; 30: 165-80.
57. Zullino DF, Riquier F. Venlafaxine and vivid dreaming. Journal of Clinical Psychiatry 2000; 61: 600.
58. Rush AJ, Armitage R, Gillin JC et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biology Psychiatry 1998; 44: 3-14.
59. Hicks JA, Argyropoulos SV, Bich AS et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. British Journal of Psychiatry 2002; 180: 528-35.
60. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology 1996; 14: 437-42.
61. Wolf P, Roder-Wanner UU, Brede M. Influence of therapeutic phenobarbital and phenytoin medication on the polygraphic sleep of patients with epilepsy. Epilepsia 1984; 25: 467-75.
62. Gigli GL, Placidi F, Diomedi M et al. Nocturnal sleep and daytime somnolence in untreated patients with temporal lobe epilepsy: changes after treatment with controlled-release carbamazepine. Epilepsia 1997; 38: 696-701.
63. Herranz JL, Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients. Epilepsia 1982; 23: 203-14.
64. Harding GFA, Alford CA, Powell TE. The effect of sodium valproate on sleep, reaction times, and visual evoked potential in normal subjects. Epilepsia 1985; 26: 597-601.
65. Monteleone P, Tortorella A, Borriello R et al. Suppression of nocturnal plasma melatonin levels by evening administration of sodium valproate in healthy humans. Biology Psychiatry 1997; 41: 336-41.
66. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002; 43: 1493-7.
67. Gourlay SG, Forbes A, Martinet T, McNeil JJ. Predictors and timing of adverse experiences during trandsdermal nicotine therapy. Drug Safety 1999; 20: 545-55.
68. Murata M, Harada M, Kato S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplantation 1999; 24: 1065-71.
69. Frank B, Perdrizet GA, White HM et al. Neurotoxicity of FK 506 in liver transplant recipients. Transplantation Proceedings 1993; 25: 1887-8.
70. Neuhaus P, McMaster P, Calne R et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transplant Internation 1994; 7: S27-31.
71. Jacobi J, Fraser GL, Coursin DB et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Critical Care Medicine 2002; 30: 119-41.
72. Heck AH, Haffmans PM, de Groot IW, Hoencamp E. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophrenia Research 2000; 46: 97-105.
73. Yamashita H, Morinobu S, Yamawaki S, Horiguchi J, Nagao M. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Research 2002; 109: 137-42.
74. Cammarano WB, Pittet JF, Weitz S, Schlobohm M, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical Care Medicine 1998; 26: 676-84.
75. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Archives of General Psychiatry 1985; 42: 1063-6.
76. Brook AD, Ahrens TS, Schaiff R et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical Care Medicine 1999; 27: 2609-15.
77. De Deyne C, Struys M, Decruyenaere J et al. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients. Intensive Care Medicine 1998; 24: 1294-8.
78. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. New England Journal of Medicine 2000; 342: 1471-7.
79. Buckley PM. Propofol in patients needing long-term sedation in intensive care: an assessment of the development of tolerance. A pilot study. Intensive Care Medicine 1997; 23: 969-74.
80. Au J, Walker WS, Scott DH. Withdrawal syndrome after propofol infusion. Anaesthesia 1990; 45: 741-2.
81. Grant IS, Worsley M. Withdrawal syndrome after propofol. Anaesthesia 1991; 46: 238.
82. Imray JM, Hay A. Withdrawal syndrome after propofol. Anaesthesia 1991; 46: 704.
83. Valente JF, Anderson GL, Branson RD et al. Disadvantages of prolonged propofol sedation in the critical care unit. Critical Care Medicine 1994; 22: 710-2.
84. Haddad PM. Antidepressant discontinuation syndromes. Drug Safety 2001; 24: 183-97.
85. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. British Journal of Clinical Pharmacology 1996; 42: 757-63.
86. Douglas NJ. Sleep in patients with chronic obstructive pulmonary disease. Clinics in Chest Medicine 1998; 19: 115-25.
87. Rampello L, Raffaele R, Nicoletti G et al. Neurobehavioral syndrome induced by H2-receptor blocker withdrawal: possible role of prolactin. Clinical Neuropharmacology 1997; 20: 49-54.
88. Watson R, Bakos L, Compton P, Gawin F. Cocaine use and withdrawal: the effect on sleep and mood. American Journal of Alcohol and Drug Abuse 1992; 18: 21-8.
89. Mayer SA, Chong JY, Ridgway E et al. Delirium from nicotine withdrawal in neuro-ICU patients. Neurology 2001; 57: 551-3.
90. Walder B, Francioli D, Meyer JJ, Lancon M, Romand JA. Effects of guidelines implementation in a surgical intensive care unit to control nighttime light and noise levels. Critical Care Medicine 2000; 28: 2242-7.
91. Wallace CJ, Robins J, Alvord LS, Walker JM. The effect of earplugs on sleep measures during exposure to simulated intensive care unit noise. American Journal of Critical Care 1999; 8: 210-9.
92. Krachman SL, Quaranta AJ, Berger TJ, Criner GJ. Effects of noninvasive positive pressure ventilation on gas exchange and sleep in COPD patients. Chest 1997; 112: 623-8.
93. Takasaki Y, Orr D, Popkin J et al. Effect of nasal continuous positive airway pressure on sleep apnea in congestive heart failure. American Review of Respiratory Diseases 1989; 140: 1578-84.
94. Willson GN, Wilcox I, Piper AJ et al. Noninvasive pressure preset ventilation for the treatment of Cheyne-Stokes respiration during sleep. European Respiratory Journal 2001; 17: 1250-7.
95. Self TH, Redmond AM, Nguyen WT. Reassessment of theophylline use for severe asthma exacerbation: Is it justified in critically ill hospitalized patients? Journal of Asthma 2002; 39: 677-86.
96. Wetter DW, Fiore MC, Baker TB, Young TB. Tobacco withdrawal and nicotine replacement influence objective measures of sleep. Journal of Consulting and Clinical Psychology 1995; 63: 658-67.
97. Roehrs T, Papineau K, Rosenthal L, Roth T. Ethanol as a hypnotic in insomniacs. self administration and effects on sleep and mood. Neuropsychopharmacology 1999; 20: 279-86.
98. Biberdorf DJ, Steens R, Millar TW, Kryger MH. Benzodiazepines in congestive heart failure. Effects of temazepam on arousability and Cheyne-Stokes respiration. Sleep 1993; 16: 529-38.
99. Merlotti L, Roehrs T, Koshorek G et al. The dose effects of zolpidem on the sleep of healthy normals. Journal of Clinical Psychopharmacology 1989; 9: 9-14.
100. Cluydts R, De Roeck J, Cosyns P, Lacante P. Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem. Journal of Clinical Psychopharmacology 1995; 15: 132-7.
101. Zimovane Summary of Product Characteristics. Rhone-Poulenc Rorer Ltd, August, 2001. Available from: http://emc.vhn.net. (February 2003).
102. Thompson DF, Pierce DR. Drug-induced nightmares. Annals of Pharmacotherapy 1999; 33: 93-8.
103. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep. A post-marketing surveillance of 16944 cases. International Clinical Psychopharmacology 1998; 13: 157-67.
104. Treggiari-Venzi M, Borgeat A, Fuchs-Buder T, Gachoud JP, Suter PM. Overnight sedation with midazolam or propofol in the ICU. Effects on sleep quality, anxiety and depression. Intensive Care Medicine 1996; 22: 1186-90.
105. Piccione P, Zorick F, Lutz T et al. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. Journal of International Medical Research 1980; 8: 361-7.
106. Rijnders RJ, Laman DM, Van Diujn H. Cyproheptadine for posttraumatic nightmares. American Journal of Psychiatry 2000; 157: 1524-5.
107. Dugovic C, Wauquier A, Janssen PA. Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology 1989; 28: 1431-3.
108. Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO. Melatonin secretion after surgery. Lancet 2000; 356: 1244-5.
109. Shilo L, Dagan Y, Smorjik Y et al. Patients in the intensive care unit suffer from severe lack of sleep associated with loss of normal melatonin secretion pattern. American Journal of the Medical Sciences 1999; 317: 278-81.
110. Mundigler G, Delle-Karth G, Koreny M et al. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Critical Care Medicine 2002; 30: 536-40.
111. Shigeta H, Yasui A, Nimura Y et al. Postoperative delirium and melatonin levels in elderly patients. American Journal of Surgery 2001; 182: 449-54.
112. Shilo L, Dagan Y, Smorjik Y et al. Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiology International 2000; 17: 71-6.
113. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine 1999; 159: 2456-60.
114. Zhdanova IV, Wurtman PJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996; 19: 423-31.